MedTrace Logo

Genotropin Treatment In Very Young Children Born Small For Gestational Age

NCT00627523 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2014-11-04

Study results available
· View outcomes & findings →

Summary

To demonstrate the effect on height and psychomotor development of Growth Hormone treatment in very young children starting at an age of 2 years.

Conditions

  • Infant, Small for Gestational Age

Interventions

DRUG

Genotropin (PN-180,307) Somatropin

Injectable Genotropin

DRUG

Control-no treatment

Control-no treatment

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Months
Max Age
29 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Belgium
  • Czechia
  • France
  • Germany
  • Italy
  • Netherlands
  • Spain
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00627523 on ClinicalTrials.gov